trending Market Intelligence /marketintelligence/en/news-insights/trending/kJe84Ajrd6Eh4RPvMtsskg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers' Opdivo meets endpoint in gastric cancer study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bristol-Myers' Opdivo meets endpoint in gastric cancer study

Bristol-Myers Squibb Co.'s Opdivo achieved the desired efficacy and safety benchmarks in a phase 3 clinical trial involving patients with advanced gastric cancer who become intolerant to chemotherapy.

The drug significantly reduced the risk of death by 37% in patients suffering from the cancer when compared to placebo.

Opdivo was co-developed by Bristol-Myers and Ono Pharmaceutical Co. Ltd., and is already approved for the treatment of unresectable or metastatic melanoma, either as a single agent or in combination with Yervoy.